2001
DOI: 10.1053/jhep.2001.26512
|View full text |Cite
|
Sign up to set email alerts
|

Lamivudine Treatment Is Beneficial in Patients With Severely Decompensated Cirrhosis and Actively Replicating Hepatitis B Infection Awaiting Liver Transplantation: A Comparative Study Using A Matched, Untreated Cohort

Abstract: Uncontrolled studies have suggested a beneficial effect of lamivudine in patients with decompensated cirrhosis caused by replicating hepatitis B virus (HBV). We analyzed the outcome of lamivudine treatment in 23 consecutive patients with severely decompensated HBV-cirrhosis defined as a Child-Pugh-Turcotte (CPT) score of >10, and compared with a historical untreated control group of 23 patients matched for age, gender, and baseline CPT score. Significant clinical response, defined as a decrease in the CPT scor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
178
4
8

Year Published

2001
2001
2018
2018

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 254 publications
(193 citation statements)
references
References 27 publications
3
178
4
8
Order By: Relevance
“…Today, not only LAM but also other new drugs, such as adefovir and entecavir, are vigorously used for chronic hepatitis B [12][13][14][15][16]. LAM, the first agent of this category, was reported to decrease the incidence of HBV-related HCC [14,17,18].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Today, not only LAM but also other new drugs, such as adefovir and entecavir, are vigorously used for chronic hepatitis B [12][13][14][15][16]. LAM, the first agent of this category, was reported to decrease the incidence of HBV-related HCC [14,17,18].…”
Section: Discussionmentioning
confidence: 99%
“…LAM has been shown to be safe and well tolerated in patients with HBV infection, including those with severely decompensated cirrhosis [12][13][14]. With the inhibition of HBV replication, inflammatory reaction in the liver subsides and the liver can be protected from further deterioration in function.…”
Section: Introductionmentioning
confidence: 99%
“…This applies also to acute fibrosis occurring in a liver with significant chronic fibrosis or cirrhosis. Indeed, the dramatic improvement in clinical status that follows successful treatment of hepatitis B in the setting of cirrhosis (Villeneuve et al, 2000;Yao et al, 2001) suggests that the acute component of acute-on-chronic fibrosis is disproportionately responsible for hepatocellular dysfunction. Over time, changes occur that render fibrosis irreversible.…”
Section: Time-course and Reversibility Of Fibrosismentioning
confidence: 99%
“…54 This study was conducted in patients with e antigen-negative disease in which immuneinduced HBeAg seroconversion is not an option; therefore, the benefit of therapy is from the direct antiviral effect of the drug. Indeed, a decrease in viral load through antiviral therapy has been associated with histologic improvement, 26,27,[55][56][57][58][59][60][61] increased survival of patients with decompensated liver disease from hepatitis B, [62][63][64][65][66][67][68][69][70] and improved clinical outcome in patients with HBV reactivation following chemotherapy. 50,52,[71][72][73][74][75][76][77][78][79][80][81] Our analyses are conservative in the following aspects.…”
mentioning
confidence: 99%